|
Thu, 12/05/2019 - 13:01 |
LYNPARZA (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer |
Merck |
|
Tue, 06/18/2019 - 11:45 |
LYNPARZA (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer |
Merck |
|
Mon, 04/29/2019 - 09:23 |
LYNPARZA (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer |
Merck |
|
Thu, 12/20/2018 - 03:42 |
LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:35 |
LYNPARZA (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:08 |
Lynparza approved by US FDA for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer |
AstraZeneca |
|
Wed, 12/05/2018 - 21:55 |
FDA Approves Genentechs Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer |
Genentech |
|
Mon, 12/03/2018 - 08:17 |
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company |
GlaxoSmithKline |
|
Mon, 11/12/2018 - 06:07 |
FDA Accepts Regulatory Submission for LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review |
Merck |
|
Tue, 10/16/2018 - 13:13 |
U.S. FDA Grants LYNPARZA (olaparib) Orphan Drug Designation for Pancreatic Cancer |
Merck |
|
Mon, 10/15/2018 - 20:43 |
US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer |
AstraZeneca |
|
Tue, 09/04/2018 - 23:58 |
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC) |
Genentech |
|
Tue, 07/17/2018 - 18:05 |
FDA Grants Breakthrough Therapy Designation for Genentechs TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC) |
Genentech |
|
Mon, 07/02/2018 - 04:58 |
LYNPARZA (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer |
Merck |
|
Tue, 06/26/2018 - 19:45 |
LYNPARZA (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer |
Merck |
|
Wed, 06/13/2018 - 12:03 |
FDA Approves Genentechs Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery |
Genentech |
|
Wed, 06/13/2018 - 10:14 |
FDA approves Roches Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery |
Rocheusa |
|
Tue, 05/08/2018 - 06:34 |
Lynparza tablets receive EU approval for the treatment of platinum-sensitive relapsed ovarian cancer |
AstraZeneca |
|
Sat, 05/05/2018 - 23:51 |
FDA Grants Priority Review to Genentechs Cancer Immunotherapy Tecentriq (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer |
Genentech |
|
Sat, 04/14/2018 - 23:56 |
Updated Overall Survival Data for LYNPARZA (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR |
Merck |
|
Tue, 04/03/2018 - 04:25 |
The European Medicines Agency Accepts Regulatory Submission for LYNPARZA (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer |
Merck |
|
Sat, 03/24/2018 - 23:32 |
Phase III IMpower150 Study Showed Genentechs TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Carboplatin and Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared to Avastin Plus Carboplatin and Paclitaxel |
Genentech |
|
Fri, 02/23/2018 - 06:04 |
LYNPARZA (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer |
Merck |
|
Fri, 02/23/2018 - 03:35 |
Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer |
AstraZeneca |
|
Fri, 01/19/2018 - 15:07 |
LYNPARZA (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer |
Merck |
